Description
Pathophysiological Aspects of Proteases in Cancer provides a comprehensive overview of the multifaceted field of proteases in the cellular environment and focuses on the recently elucidated functions of complex proteolytic systems in physiology and pathophysiology. The book both gives insights on the general aspects of the role of proteases in cancer, their role as diagnostics and prognostics biomarkers, their impact on chemoresistance, and the future cutting-edge technologies like cocktail therapies and Cyber Knife technology. Given the breadth and depth of information covered in the respective contributions, the book will be immensely useful for researchers in oncology and working to identify targets for drug development.Multidisciplinary in scope, the book bridges the gap between fundamental and translational research, with applications in the biomedical and pharmaceutical industry, making it a thought-provoking read for basic and applied scientists engaged in biomedical research.- Gives insight into the spectrum of proteases, protease inhibitors, and protease interactors involved at the cellular and molecular level in cancer development- Gives a comprehensive overview of the role of proteases in modulating cellular metabolism and chemoresistance to better understand how proteases play in early to the end point in cancer development and metastasis- Provides a multidisciplinary approach demonstrating the biochemical and signal transduction mechanisms associated with dysregulation of proteases, leading to the manifestation of various diseases- Highlights the roles and regulation of different types of proteases, as well as their synthetic and endogenous inhibitors- Bridges the gap between fundamental and translational research, with applications in the biomedical and pharmaceutical industry
Table of Contents
Section I: General Aspects1. Pathophysiological aspects of calpains in cancer2. Mitochondrial proteases in cancer development and progression3. Proteases in Head and Neck Cancer4. Matrix metalloproteases and uveal melanomas5. Proteases in DNA damage, repair and radio resistance: Cellular and Molecular aspects6. Radiotherapy, proteases and gastric cancer: a complex interplay7. Matrix metalloproteases in the pathogenesis of hepatocarcinoma8. Exploring synthetic and natural compounds for Cathepsin B: Mechanisms and therapy9. Kallikrein-related peptidase 3 (KLK3) as valuable biomarkers for prostate cancer10. Ubiquitin –specific protease 3,7 in bone cancer and squamous cell carcinoma11. Serine protease: structure, classification, mechanism and role in breast cancer Section II: Proteases as Diagnostics and Prognostics Biomarkers12. Protease activator receptor-1 and matrix metalloproteinase-1 as prognostic factors and novel therapeutic targets for gastric cancer13. Matrix metalloproteases as diagnostic and prognostic biomarkers in cancer14. From enzyme to predictors: Serine proteases in cancer diagnosis and prognosis15. Cathepsins as a diagnostic and prognostic marker in Oral cancer16. Role of Kallikreins in Prostate Cancer17. Mechanistic aspects of Serine Protease as biomarkers in wound healing of lung cancer18. The role of acetylcholinesterase in cancer development and possible therapeutic applications19. Therapeutics of animal derived compounds in proteases induced cancer20. Molecular Warriors: Proteases as Sentinels in the War Against Cancer Diagnosis and Prognosis Section III: Proteases, Chemoresistance and Cancer21. Serine proteases, chemoresistance and cancer22. Cathepsins, chemoresistance and cancer23. ix metalloproteases, chemoresistance and cancer24. MMPs (-2 and -9) mediated drug resistance and their reversal in gynecological cancer25. The link between trypsinogen and chymotrypsinogen in gastrointestinal cancer26. Role of the proteasome in the development of chemoresistance in multiple myeloma27. Role of cysteine cathepsin and matrix metalloproteases in progression and chemoresistance in ovarian and breast cancer28. Proteases, chemoresistance and cancer29. Breaking Barriers: Proteases as Key Players in Cancer Chemoresistance Section IV: Other Aspects30. Matrix metalloproteases-targeting low molecular weight compound31. Synthetic protease inhibitors in oral, head and neck cancer: evidence from clinical trials.32. Synthetic protease inhibitors in endocrine and gastroenterology cancers: results of clinical trials33. Side effects of synthetic protease inhibitors used in gynecology cancers34. Role of synthetic compounds with protease inhibitory activity in breast cancer35. Cathepsin responsive nanomaterials for targeted delivery of malignant tumors
